HAIC Combined With Toripalimab and Donafenib for Advanced BTC

NCT ID: NCT05350943

Last Updated: 2022-10-18

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-03-01
• Study Completion Date: 2023-11-30

Brief Summary

This is a single center, single arm, phase II, prospective study to evaluate the efficacy and safety of Hepatic Arterial Infusion Chemotherapy (HAIC) combined with PD-1 inhibitor immunotherapy Toripalimab and Tyrosine Kinase Inhibitor Donafenib in patients with advanced biliary tract cancer.

Conditions

Biliary Tract Adenocarcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HAIC+Toripalimab+Donafenib

HAIC(GEMOX)+Toripalimab+Donafenib

Group Type: EXPERIMENTAL

HAIC

Intervention Type: PROCEDURE

After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.

Gemcitabine

Intervention Type: DRUG

1000 mg/m\^2 in 100ml saline solution IV, d1, Q3W

Oxaliplatin

Intervention Type: DRUG

85 mg/m\^2 in 500ml 5% glucose solution over 2 hours IV, d1, Q3W

Toripalimab

Intervention Type: DRUG

3mg/kg (body weight \< 60kg) or 240 mg（body weight\>= 60kg）in 250 saline soluation, IV, Q3W

Donafenib

Intervention Type: DRUG

0.2mg. P.O, BID, continuously

Interventions

HAIC

After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.

Intervention Type: PROCEDURE

Gemcitabine

1000 mg/m\^2 in 100ml saline solution IV, d1, Q3W

Intervention Type: DRUG

Oxaliplatin

85 mg/m\^2 in 500ml 5% glucose solution over 2 hours IV, d1, Q3W

Intervention Type: DRUG

Toripalimab

3mg/kg (body weight \< 60kg) or 240 mg（body weight\>= 60kg）in 250 saline soluation, IV, Q3W

Intervention Type: DRUG

Donafenib

0.2mg. P.O, BID, continuously

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 18 to 80 years of age, of any sex;
• Histologically/Cytologically confirmed diagnosis of unresectable advanced adenocarcinoma of the gallbladder, intrahepatic bile duct and extrahepatic bile duct.
• At least one measurable lesion umder CT/MRI as defined by RECIST1.1 criteria
• Patients must have adequate organ and marrow function as defined below:

Blood test:

Hemoglobin (HB) ≥90 g/L Absolute neutrophil count (ANC) ≥1.5×10^9/L； Platelet (PLT) ≥80×10^9/L；

Biochemical test:

total bilirubin≤2×ULN (institutional upper limit of norm) AST(SGOT)/ALT(SGPT)≤2.5 ×ULN creatinine clearance≥ 50 ml/min as calculated by the Cockroft-Gault formula

• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-1;
• Indocyanine Green Retention Rates at 15 min (ICGR15<22%;
• Life expectancy of > 3 months;

Exclusion Criteria

• Patients with other malignant tumors should be excluded
• Female patients who are pregnant or breast-feeding. Female patients who are pregnant during the study should also exit.
• Patient has enter any other clinical trails within 4 weeks prior to study entry.
• Patient known with a severe and/or uncontrolled medical disease.
• Chronic non-healing wound/bone fracture
• History of organ transplant
• Patients with abnormal coagulation function (PT>16s, APTT>43s, TT>21s, Fbg<2g/L), those have bleeding tendency (14 days prior to randomization must meet: INR is within the normal range without any use of anticoagulants); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or analogous therapy; use for preventive purposes is permitted provided that the international normalized ratio of prothrombin time (INR) ≤ 1.5, take low-dose warfarin (1 mg PO, QD) or low-dose aspirin (do not exceed 100 mg per day);
• Previous history of aterial/venous thrombosis such as cerebrovascular accidents, pulmonary embolism or deep venous thrombosis within one year prior to patients recruitment.
• Hitstory of psychiatric drug abuse and hasn't come clean, or with psychiatric illness/social situations that would limit compliance with study requirements
• History of immunodeficiency, or other acquired/congenital immunodeficiency diseases
• Concomitant diseases that severely endanger the safety of the subject or affect the study completion according to the judgment of the investigator
• Willingness to sign a written informed consent document, with good compliance.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Lu Wang, MD, PhD

OTHER

Sponsor Role: lead

Responsible Party

Lu Wang, MD, PhD

professor

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Fudan University Shanghai Cancer Center

Shanghai, , China

Countries

China

Other Identifiers

2021-GZWK-04

Identifier Type: -

Identifier Source: org_study_id